Clinical Trials Browser

Phase 1/2 × Not yet recruiting × 90 days × Clear all

NCT06303193 2026-03-18

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Not yet recruiting

Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06991738 2026-03-18

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Phase 1/2 Not yet recruiting

Thyroid Neoplasms

NCT07328490 2026-03-18

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07416188 2026-03-18

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Phase 1/2 Not yet recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT07437963 2026-03-18

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT07463807 2026-03-18

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479485 2026-03-18

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Phase 1/2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07477444 2026-03-17

HER-OIC

Phase 1/2 Not yet recruiting

Gastrointestinal

Gastroesophageal Cancer

NCT07387354 2026-03-16

MDS

Phase 1/2 Not yet recruiting

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT07472322 2026-03-16

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Phase 1/2 Not yet recruiting

Carcinoma, Merkel Cell

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07468851 2026-03-13

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Phase 1/2 Not yet recruiting

High-risk Non-muscle-invasive Bladder Cancer

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT07468071 2026-03-12

KontRASt-R

Phase 1/2 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07372885 2026-03-11

GRACE

Phase 1/2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07459998 2026-03-10

SKB103 for Injection in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07460375 2026-03-10

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07460986 2026-03-10

BEXAR

Phase 1/2 Not yet recruiting

Sarcoma

NCT07225985 2026-03-06

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07454187 2026-03-06

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07455734 2026-03-06

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT07453225 2026-03-05

Empirical Radioactive Iodine Therapy in DTC

Phase 1/2 Not yet recruiting

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07346144 2026-03-04

ADePT

Phase 1/2 Not yet recruiting

Glioblastoma

NCT07354100 2026-03-04

(BLOOM)

Phase 1/2 Not yet recruiting

Neoplasms

NCT07444541 2026-03-03

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07446725 2026-03-03

A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT07446855 2026-03-03

PARTHENON

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumours

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT07441889 2026-03-02

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Phase 1/2 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07435584 2026-02-27

EVER-RECODE

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07436728 2026-02-27

A Study of TAK-505 in Adults With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Malignant Solid Tumors

NCT07439094 2026-02-27

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07439653 2026-02-27

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, B-Cell

NCT07336472 2026-02-25

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07283679 2026-02-24

Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, B-Cell

NCT07431216 2026-02-24

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Phase 1/2 Not yet recruiting

Glioblastoma

NCT07428148 2026-02-23

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

Phase 1/2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT07408583 2026-02-19

Prenatal Transplantation for Fetuses With Fanconi Anemia

Phase 1/2 Not yet recruiting

Classical hematology

Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Fanconi Anemia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Anemia, Hypoplastic, Congenital, Genetic Diseases, Inborn, DNA Repair-Deficiency Disorders

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07421856 2026-02-19

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms